Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial

In this study, 231 patients with TRD were treated with R-107 120 mg per day for 5 days, and 168 (72.7%) were included as an enriched responder population who were randomized to a range of double-blind R-107 doses or placebo for the next 12 weeks. In this double-blind phase, the 180 mg…